Sfakianos J P, Hakimi A A, Kim P H, Zabor E C, Mano R, Bernstein M, Karellas M, Russo P
Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Eur J Surg Oncol. 2014 Dec;40(12):1700-5. doi: 10.1016/j.ejso.2014.04.010. Epub 2014 Apr 24.
To report our experience on surgical resection of renal tumors for patients with a history of chronic anticoagulation (ACT) or aspirin use.
We performed a retrospective analysis of 2473 patients who underwent surgery for renal tumors between 2005 and 2012. Prior to surgery, 172 were on chronic ACT and 695 on aspirin. Multivariable linear and logistic regression models were used to compare transfusion and overall complication rates between patients undergoing renal surgery who were on therapy to patients who were on aspirin and to patients with no therapy.
Compared to no therapy and aspirin patients those on ACT were older (57.3 (IQR 48.4-66.10) vs 63.9, (IQR 57.3-71.5) vs 68.4, (IQR 60.4-73.5); p < 0.001), with a higher percentage having an ASA score of 3 or 4 (42.4 vs 57.9 vs 82.6%; p < 0.001), respectively. ACT patients had a higher 30-day transfusion rate, 22.7% vs 7.6% vs 6.9%, and 90-day complication rate, 17.4% vs 7.2% vs 7.3%, both p < 0.001. The median length of stay differed statistically between groups (p < 0.001), with a modest longer stay in the anticoagulation group (OR 1.11 SE 0.26; p < 0.001). Transfusion and complication rates for patients on therapy undergoing minimally invasive surgery vs open surgery were not statistically different.
Patients on chronic ACT had higher transfusion and overall complication rates compared to patients on no treatment or on chronic aspirin. These findings did not correlate to clinical differences in length of stay or grade 3-5 complications.
报告我们对有长期抗凝治疗(活化凝血时间[ACT])史或服用阿司匹林的肾肿瘤患者进行手术切除的经验。
我们对2005年至2012年间接受肾肿瘤手术的2473例患者进行了回顾性分析。术前,172例患者接受长期ACT治疗,695例患者服用阿司匹林。采用多变量线性和逻辑回归模型,比较接受肾手术治疗的患者与服用阿司匹林的患者以及未接受治疗的患者之间的输血率和总体并发症发生率。
与未接受治疗的患者和服用阿司匹林的患者相比,接受ACT治疗的患者年龄更大(分别为57.3岁[四分位间距48.4 - 66.10]、63.9岁[四分位间距57.3 - 71.5]、68.4岁[四分位间距60.4 - 73.5];p < 0.001),ASA评分为3或4的患者比例更高(分别为42.4%、57.9%、82.6%;p < 0.001)。ACT治疗的患者30天输血率更高,分别为22.7%、7.6%、6.9%,90天并发症发生率分别为17.4%、7.2%、7.3%,p均< 0.001。各组间住院时间中位数存在统计学差异(p < 0.001),抗凝治疗组住院时间略长(比值比1.11,标准误0.26;p < 0.001)。接受治疗的患者进行微创手术与开放手术的输血率和并发症发生率无统计学差异。
与未接受治疗或长期服用阿司匹林的患者相比,接受长期ACT治疗的患者输血率和总体并发症发生率更高。这些发现与住院时间或3 - 5级并发症的临床差异无关。